Linked Life Data

18321228

Source:http://linkedlifedata.com/resource/pubmed/id/18321228

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-3-6
pubmed:abstractText
beta-Lactam antibiotics are the most used antibacterial agents in clinical practice, but the development of resistance poses some questions about their future leading to an urgent requirement for new compounds. Specifically, beta-lactamases represent the commonest single cause of bacterial resistance to beta-lactam antibiotics. Numerous chromosomal and plasmid-mediated types are known and classified on the basis of their structure. Among them, extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamase can confer broad-spectrum antibiotic resistance to ureidopenicillins, third-generation cephalosporins and aztreonam, posing unique therapeutic challenges. Furthermore, the spreading emergence of carbapenemases is a significant threat to the management of nosocomial infections.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1744-7658
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
17
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
285-96
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Novel beta-lactam antibiotics and inhibitor combinations.
pubmed:affiliation
Azienda Ospedaliera Universitaria San Martino di Genova, Clinica Malattie Infettive, Largo R Benzi 10, 16132 Genova, Italy. mattba@tin.it
pubmed:publicationType
Journal Article, Review